Bvf Inc Hille Vax, Inc. Transaction History

Bvf Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$13.52 - $21.46 $1.81 Million - $2.87 Million	-133,873 Reduced 35.0%	248,579 $4.16 Million
Q3 2022 Nov 14, 2022	SELL	$10.5 - $22.01 $640 - $1,342	-61 Reduced 0.02%	382,452 $6.54 Million
Q2 2022 Aug 15, 2022	BUY	$8.7 - $20.18 $3.33 Million - $7.72 Million	382,513 New	382,513 $4.18 Million

40.5M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $58.8M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.